Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Graft-versus-host Disease (GvHD)
56%
Overall Survival
40%
Pretransplant
33%
Nonmyeloablative
27%
Immune Reconstitution
26%
Confidence Interval
25%
Myeloablative
24%
Non-relapse Mortality
21%
Hematopoietic Stem Cell Transplantation
21%
Myeloablative Conditioning
20%
Myelodysplastic Syndrome
15%
Hematopoietic Cell Transplantation
14%
Fludarabine
14%
Natural Killer Cells
13%
Relapse-free Survival
13%
Treosulfan
13%
Flow Cytometry
12%
Non-myeloablative Transplantation
12%
Extracorporeal Photopheresis
12%
Vitamin E
12%
Population-based Study
12%
Hazard Ratio
10%
Transplantation
10%
Denmark
10%
Cyclosporine
8%
Sexual Behavior
8%
Acute Myeloid Leukemia
8%
Immunosuppression
7%
Chronic Lymphocytic Leukemia
7%
Acute Lymphoblastic Leukemia
7%
Allogeneic Transplantation
6%
Host Disease
6%
Prognostic Biomarker
6%
Infliximab
6%
T-cell Replete
6%
Improved Outcomes
6%
Donor Lymphocyte Infusion
6%
Clonal Cytopenia of Undetermined Significance
6%
Vitamin D Status
6%
Improved Survival
6%
Strong Predictor
6%
Graft-versus-host Disease Prophylaxis
6%
Pulmonary Comorbidities
6%
Danish Population
6%
HLA-matched Donor
6%
Plasma Vitamin D
6%
Longitudinal Follow-up
6%
Primary Effusion Lymphoma
6%
Response Status
6%
Medicine and Dentistry
Allogeneic Hematopoietic Stem Cell Transplantation
37%
Acute Graft Versus Host Disease
30%
Overall Survival
24%
Myelodysplastic Syndrome
21%
Cell Transplantation
18%
Hematopoietic Stem Cell
18%
Graft Versus Host Reaction
13%
Flow Cytometry
12%
Hematopoietic Stem Cell Transplantation
12%
Cytopenia
12%
Photopheresis
12%
Alpha Tocopherol
12%
Disease
12%
T Cell
12%
Ibrutinib
12%
B-Cell Chronic Lymphocytic Leukemia
12%
Minimal Residual Disease
12%
Venetoclax
12%
Hazard Ratio
11%
Chronic Graft Versus Host Disease
10%
Myeloablative Conditioning
9%
Cyclosporine
9%
Hematologic Malignancy
9%
Cohort Analysis
9%
Conditioning
8%
Acute Myeloid Leukemia
8%
Fludarabine
7%
Acute Lymphoblastic Leukemia
7%
Diagnosis
7%
Bone Marrow Transplantation
7%
Allotransplantation
6%
Treosulfan
6%
Donor Lymphocyte Infusion
6%
Systematic Review
6%
Vitamin D
6%
Immunosuppressive Treatment
6%
Primary Effusion Lymphoma
6%
Allogeneic Stem Cell Transplantation
6%
Natural Killer Cell
6%
Prophylaxis
6%
T-Cell Lymphoma
6%
Pleura Effusion
6%
Cross Sectional Study
6%
Nucleosome
6%
Myelofibrosis
6%
Cumulative Incidence
5%
Transplantation
5%
Mycophenolic Acid
5%
Immunology and Microbiology
Acute Graft Versus Host Disease
43%
Cell Transplantation
42%
Hematopoietic Cell
42%
Allogeneic Hematopoietic Stem Cell Transplantation
40%
Overall Survival
37%
Immune Reconstitution
20%
Allogeneic Stem Cell Transplantation
18%
Conditioning
17%
Blood Plasma
15%
T Cell
14%
Graft-Versus-Host Disease
14%
Natural Killer Cell
13%
Hematopoietic Stem Cell Transplantation
13%
Recurrence Free Survival
13%
Myeloid
12%
Vitamin E
12%
Chronic Graft Versus Host Disease
11%
Lymphocyte
9%
Vitamin Blood Level
8%
Morphology
8%
Immunosuppression
7%
C-Reactive Protein
7%
Allotransplantation
7%
Host
6%
Infliximab
6%
Prognostic Biomarker
6%
Comorbidity
6%
Lung Function
6%
Precursor
6%
Gamma Delta T-Cell
6%
T Cell Receptor
6%
Cytokine Response
6%
Leukocyte
6%
Nucleosome
6%
Mycophenolic Acid
5%
